Literature DB >> 3811235

Infectious influenza A and B virus variants with long carboxyl terminal deletions in the NS1 polypeptides.

G P Norton, T Tanaka, K Tobita, S Nakada, D A Buonagurio, D Greenspan, M Krystal, P Palese.   

Abstract

An influenza A virus, A/turkey/Oregon/71, was shown by protein gel analysis to code for an NS1 protein approximately half the size of those of other influenza A viruses. Sequence analysis of the NS gene of this virus revealed a 10 nucleotide deletion resulting in an NS1 protein of only 124 amino acids. This truncated NS1 polypeptide retained its karyophilic pattern as detected by indirect immunofluorescence analysis of virus infected cells. Also, A/turkey/Oregon/71 virus grew to high titer in embryonated chicken eggs comparable to other influenza A viruses. We also identified a laboratory variant of an influenza B virus, clone 201, which codes for a truncated NS1 protein. Sequence analysis revealed a 13 nucleotide deletion resulting in a shortened NS1 protein of only 127 amino acids as compared to other influenza B virus NS1 proteins possessing a length of 281 amino acids. Again as shown for the NS1 proteins of other influenza B viruses the NS1 polypeptide of B virus clone 201 was found to localize in the nucleus of infected cells. It appears that large deletions in the carboxyl terminus of the NS1 proteins of influenza A and B viruses can be tolerated without affecting the functional integrity of the NS1 polypeptide.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3811235     DOI: 10.1016/0042-6822(87)90399-0

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  28 in total

1.  Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein.

Authors:  J Talon; C M Horvath; R Polley; C F Basler; T Muster; P Palese; A García-Sastre
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Dynamics of biologically active subpopulations of influenza virus: plaque-forming, noninfectious cell-killing, and defective interfering particles.

Authors:  Philip I Marcus; John M Ngunjiri; Margaret J Sekellick
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

3.  Characterization of influenza virus NS1 protein by using a novel helper-virus-free reverse genetic system.

Authors:  M Enami; K Enami
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Evolution of the NS genes of the influenza A viruses. II. Characteristics of the amino acid changes in the NS1 proteins of the influenza A viruses.

Authors:  K Nakajima; E Nobusawa; S Nakajima
Journal:  Virus Genes       Date:  1990-06       Impact factor: 2.332

5.  The N-terminal half of the influenza virus NS1 protein is sufficient for nuclear retention of mRNA and enhancement of viral mRNA translation.

Authors:  R M Marión; T Aragón; A Beloso; A Nieto; J Ortín
Journal:  Nucleic Acids Res       Date:  1997-11-01       Impact factor: 16.971

6.  Regulation of a nuclear export signal by an adjacent inhibitory sequence: the effector domain of the influenza virus NS1 protein.

Authors:  Y Li; Y Yamakita; R M Krug
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

Review 7.  Variability among the neuraminidase, non-structural 1 and PB1-F2 proteins in the influenza A virus genome.

Authors:  William G Dundon
Journal:  Virus Genes       Date:  2012-01-20       Impact factor: 2.332

8.  Two nuclear location signals in the influenza virus NS1 nonstructural protein.

Authors:  D Greenspan; P Palese; M Krystal
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  Analysis of influenza B Virus NS1 protein trafficking reveals a novel interaction with nuclear speckle domains.

Authors:  Jana Schneider; Bianca Dauber; Krister Melén; Ilkka Julkunen; Thorsten Wolff
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

10.  Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication.

Authors:  Kerstin Wunderlich; Daniel Mayer; Charlene Ranadheera; Anne-Sophie Holler; Benjamin Mänz; Arnold Martin; Geoffrey Chase; Werner Tegge; Ronald Frank; Ulrich Kessler; Martin Schwemmle
Journal:  PLoS One       Date:  2009-10-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.